"Leukemia, Hairy Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
| Descriptor ID |
D007943
|
| MeSH Number(s) |
C04.557.337.415 C15.604.515.553 C20.683.515.517
|
| Concept/Terms |
Leukemia, Hairy Cell- Leukemia, Hairy Cell
- Leukemic Reticuloendotheliosis
- Leukemic Reticuloendothelioses
- Reticuloendothelioses, Leukemic
- Reticuloendotheliosis, Leukemic
- Hairy Cell Leukemia
- Hairy Cell Leukemias
- Leukemias, Hairy Cell
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Hairy Cell".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Hairy Cell".
This graph shows the total number of publications written about "Leukemia, Hairy Cell" by people in this website by year, and whether "Leukemia, Hairy Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Hairy Cell" by people in Profiles.
-
Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma. 2024 Sep; 65(9):1325-1334.
-
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023 03 02; 141(9):996-1006.
-
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022 12 13; 12(12):165.
-
The pharmacological management of hairy cell leukemia. Expert Opin Pharmacother. 2020 Aug; 21(11):1337-1344.
-
Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax. Am J Hematol. 2018 12; 93(12):1568-1569.
-
Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018 11; 31(11):1717-1732.
-
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 11; 15(11):1414-1427.
-
Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood. 2017 03 16; 129(11):1563.
-
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep; 174(5):760-6.
-
The importance of the tissue microenvironment in hairy cell leukemia. Best Pract Res Clin Haematol. 2015 Dec; 28(4):208-16.